TSHA Taysha Gene Therapies Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Taysha Gene Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update

   Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022
   

   Received Orphan Drug Designation from the European Commission for TSHA-120 for giant axonal neuropathy (GAN) and recently completed commercially representative GMP batch; regulatory update expected in mid-2022

   Existing cash and cash equivalents, along with full access to the term loan facility, is expected to fund operating expenses and capital requirements into the fourth quarter of 2023

   DALLAS, May 16, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing…

   View Full Article
2. 11 May 2022 Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16

   DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the first quarter ended March 31, 2022, and host a corporate update conference call and webcast on Monday, May 16, 2022, at 8:00 AM Eastern Time.
   

   Conference Call Details
   Monday, May 16, at 8:00 AM Eastern Time / 7:00 AM Central Time
   Toll Free:		877-407-0792
   International:		201-689-8263
   Conference ID:		13729044
   Webcast:		https://ir.tayshagtx.com/news-events/events-presentations

   …

   View Full Article
3. 10 May 2022 Taysha Gene Therapies Announces Presentations at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy

   DALLAS, May 10, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced oral and poster presentations and a company-sponsored symposium at the upcoming 25^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place in Washington, D.C. from May 16-19, 2022.
   

   Oral Presentations

   • 3: Vagus Nerve Delivery of AAV9 to Treat Autonomic Nervous System Dysfunction in Giant Axonal Neuropathy
     Presenter – Rachel Bailey, UT Southwestern
     Date/Time – Monday, May…

   View Full Article
4. 03 May 2022 Taysha Gene Therapies Receives Orphan Drug Designation from the European Commission for TSHA-120 for the Treatment of Giant Axon Neuropathy (GAN)

   Clinical efficacy data for TSHA-120 provide quantitative evidence of long-term durability across all therapeutic dose cohorts with a 10-point improvement in mean change in MFM32 by Year 3 compared to estimated natural history decline of 24 points
   

   Biopsy data in five of six patient samples analyzed to date confirmed active regeneration of nerve fibers following treatment with TSHA-120

   53 patient-years of clinical data support favorable safety and tolerability profile of TSHA-120

   Estimated addressable patient population of 5,000 worldwide represents a multi-billion dollar commercial opportunity

   No approved treatments for the underlying cause of the disease

   DALLAS, May 03, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies…

   View Full Article
5. 25 April 2022 Taysha Gene Therapies Announces Oral Presentations at the Upcoming 2022 IRSF Rett Syndrome Scientific Symposium and the ASCEND National Summit

   DALLAS, April 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced oral presentations at the upcoming International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Symposium taking place in Nashville, Tennessee April 26 – 27, 2022, and the ASCEND Rett Syndrome National Summit taking place in Nashville, Tennessee April 27 – 30, 2022.  
   

   IRSF Scientific Symposium Oral Presentation Details

   • Safety and Biodistribution Assessment in Non-human Primates (NHPs) of a miniMECP2 …

   View Full Article